TASK X12: THERAPEUTICS FOR NOROVIRUS
$52,225N01FY2014AINIH
Leidos, Inc., Reston VA
Investigators
Abstract
The Biopharmaceutical Product Development Services program provides services to facilitate preclinical development, for infectious diseases, of materials that are derived from biotechnology processes, such as monoclonal antibodies and derivatives of monoclonal antibodies; recombinant proteins; peptides; nucleic acid based vectors (siRNA, plasmids); and live, modified-live and/or attenuated entities.
View original record on NIH RePORTER →